Arrowhead Research Receives a Hold from Cantor Fitzgerald

By Austin Angelo

Cantor Fitzgerald analyst Elemer Piros maintained a Hold rating on Arrowhead Research (NASDAQ: ARWR) today and set a price target of $2. The company’s shares closed yesterday at $2.79.

Piros wrote:

“ARO-AAT and ARO-HBV in 1H18. Arrowhead’s lead preclinical programs are expected to have CTAs filed in 1Q18 and 2Q18, respectively. Gating items for these candidates include GLP toxicity studies (both candidates) and completion of cross reactivity studies for ARO-HBV. We are encouraged by the significant progress made and the established guidance to reach the clinic with two candidates by 1H18.”

According to, Piros is a 3-star analyst with an average return of 2.8% and a 48.9% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Dimension Therapeutics Inc, and Global Blood Therapeutics.

Arrowhead Research has an analyst consensus of Hold, with a price target consensus of $2.

Based on Arrowhead Research’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $9.34 million and GAAP net loss of $5.52 million. In comparison, last year the company earned revenue of $39.58K and had a GAAP net loss of $19.42 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.